Home
Learn More
Features & Pricing
Success Stories
Contact Us
Search Archives
PRWeb Direct
Submit Release
October 10, 2008
 
Industry Categories  
News by Country  
News by MSA  
Todays News  
Browse by Day  
PR Trackbacks™  
Featured Videos  
ViewNews™  
eBook Digests  
RSS  
PRWeb, a leader in online news and press release distribution, has been used by more than 40,000 organizations of all sizes to increase the visibility of their news, improve their search engine rankings and drive traffic to their Web site.
 
All Press Releases for April 19, 2004 Subscribe to this News Feed      
 

Antioxidant Study Results Prove Once Again that NCI Lied

Medical Research Products of Miami, Florida, April 14, 2004 The results of an independent antioxidant study showed that an alternative cancer treatment, Cancell is up to 45 times more powerful than the previous best antioxidant. This contradicts the 1990 National Cancer Institute (NCI) test summary that stated that Cancell showed no anticancer activity worthy of further study. What is going on at NCI?

(PRWEB) April 19, 2004 -- Cancell (brand names Cantron and Protocel) gained popularity in the 1980s. Since then thousands of people have used this treatment for cancer or viral infections and had some extremely positive side effects. One side effect was the reduction of blood pressure. Some users were scheduled for angioplasty surgery, but the surgery was postponed in order to treat the cancer. After treating their cancer, they pursued their old clogged artery problem only to find that their arteries were no longer clogged.

As a result of the above described side effect, Medical Research Products of Miami, the manufacturer of Cantron, initiated an antioxidant study of Cantron and Protocel. The study was performed by two independent laboratories, Brunswick and Cayman Laboratories. The research project was overseen by Daniel Hetrick, PhD.

The results of two independent laboratories were released in April 2004: Cancell (brand names Cantron and Protocel) is by far the most powerful antioxidants thus far tested it is:

Over 25 times more powerful than the previous best antioxidant against peroxyl radicals.

Over 45 times more powerful than the previous best antioxidant against hydroxyl radicals.

These results show that Cancell is the only antioxidant that is effective against both of the most dangerous and difficult to defeat free radicals. Cancell also blocked the formation of all superoxide radicals in the test system. For a table comparing Cancell against the previously best antioxidants, go to http://alternativecancer.us/

The test results fly in the face of the National Cancer Institute (NCI) test summary statement "the mixture lacked substantial anticancer activity. During the short NCI test, designed for fast working chemotherapy agents, Cancell, a slow acting treatment, reduced the mass of half of the 60 tumors tested by 80% or more. Follow this link to see summary tables of weight reduction from NCI?s own test sheets: http://alternativecancer.us/testr.htm

NCI receives $5 billion of our tax money each year to find a cure for cancer. This incredible amount of money pays the salary of many research doctors. If a cure for cancer is found, those doctors would lose their job and NCI would have to close its doors.

Ordering and protocol information can be obtained at http://alternativecancer.us/

###

OPTIONS
Printer Friendly Version
Email this story to a colleague
CONTACT INFORMATION
Paul Winter
WINTER WORKS
Email us Here
ATTACHED FILES

Tumor Weight Reduction from NCI Test Sheets
This table was compiled from the actual NCI test data sheets for Cancell.

Antioxidant Performance
The antioxidant performance of Cancell compared to the previous best performers.

ABOUT PRESS RELEASES
If you have any questions regarding information in these press releases please contact the company listed in the press release. Please do not contact PRWeb. We will be unable to assist you with your inquiry. PRWeb disclaims any content contained in these releases. Our complete disclaimer appears here.
 
Disclaimer: If you have any questions regarding information in these press releases please contact the company listed in the press release.
Please do not contact PRWeb®. We will be unable to assist you with your inquiry.
PRWeb® disclaims any content contained in these releases. Our complete disclaimer appears here.

© Copyright 1997-2008, Vocus PRW Holdings, LLC.
Vocus, PRWeb and Publicity Wire are trademarks or registered trademarks of Vocus, Inc. or Vocus PRW Holdings, LLC.

Terms of Service | Privacy Policy | Copyright